{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06414278",
            "orgStudyIdInfo": {
                "id": "2022LS089"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2023-09048",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "2022LS089",
                    "type": "OTHER",
                    "domain": "University of Minnesota/Masonic Cancer Center"
                },
                {
                    "id": "P30CA077598",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P30CA077598"
                }
            ],
            "organization": {
                "fullName": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            },
            "briefTitle": "Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy",
            "officialTitle": "Early Identification of Cognitive Side-Effects of Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "evaluation-of-early-identification-of-cognitive-side-effects-of-immunotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-02-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-08",
            "studyFirstSubmitQcDate": "2024-05-13",
            "studyFirstPostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To investigate the use of a toolkit for automated administration and scoring of cognitive tests (Stress, Language and Speech Analysis, or SALSA) in adult cancer patients who are treated with commercial chimeric antigen receptor T cell therapy (CAR-T) products at University of Minnesota and are at risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS).\n\nOUTLINE: This is an observational study.\n\nPatients complete SALSA assessment and ICE assessments on study. Patients also have their medical records reviewed on study."
        },
        "conditionsModule": {
            "conditions": [
                "Hematopoietic and Lymphatic System Neoplasm",
                "Malignant Solid Neoplasm"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 38,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Observational",
                    "description": "Patients complete SALSA assessment and ICE assessments on study. Patients also have their medical records reviewed on study.",
                    "interventionNames": [
                        "Other: Non-Interventional Study"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Non-Interventional Study",
                    "description": "Non-interventional study",
                    "armGroupLabels": [
                        "Observational"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of patients completing at least 80 percent of planned SALSA administrations during post CAR-T hospitalization",
                    "description": "Descriptive statistics will be used to summarize the feasibility of SALSA in CAR-T patients. The overall completion rate of will be calculated for each patient, as well as the pattern of completions.",
                    "timeFrame": "18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \\* \u2265 18 years of age at initiation of therapy\n\n  * Planning to undergo inpatient CAR-T therapy for primary malignancy\n  * Fluent in English (written or spoken)\n\nExclusion Criteria:\n\n* \\* Subjects with speech or hearing impediment that would make them unable to be assessed with SALSA\n\n  * Subjects with diagnosed cognitive impairment prior to CAR-T therapy\n  * Unwilling or unable to sign voluntary written consent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients planning to undergo CAR-T therapy for primary malignancy recruited through the University of Minnesota.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Veronika Bachanova",
                    "affiliation": "University of Minnesota Masonic Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Minnesota/Masonic Cancer Center",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Veronika Bachanova",
                            "role": "CONTACT",
                            "phone": "612-625-5469",
                            "email": "bach0173@umn.edu"
                        },
                        {
                            "name": "Veronika Bachanova",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}